Peer-influenced content. Sources you trust. No registration required. This is HCN.
Specialty Pharmacy Continuum
Falling Medicaid enrollment under the One Big Beautiful Bill Act is eroding the disproportionate share hospital percentages that determine 340B Drug Pricing Program eligibility at safety-net hospitals, according to a presentation at HOPA 2026.
Clinical Pharmacology May 29th 2026
GoodRx for Healthcare Professionals
The introduction of lisdexamfetamine, a generic for Vyvanse, initially showed promise in increasing access to ADHD treatment. However, it too has fallen into shortage, highlighting the ongoing challenges in meeting patient demand.
Family Medicine/General Practice September 3rd 2024
Psychiatrist.com
The recent recall of Zenzedi 30 mg tablets due to contamination stresses the importance of meticulous medication management and awareness of the broader challenges in ADHD treatment availability and safety.
Pediatrics February 21st 2024
Psych Congress Network
The stimulant crisis is affecting ADHD treatment across the board; Dr. Greg Mattingly offers crucial insights into navigating this challenging landscape. Learn about alternative treatment options to better serve your patients.
Psychiatry September 12th 2023
Medical Professionals Reference (MPR)
The DEA and FDA are addressing the current prescription stimulant shortage, emphasizing both the importance of patient access and the need for responsible prescribing. Stay informed on the latest updates and consider alternative treatments where appropriate.
Psychiatry August 8th 2023
Cancer Care Business Exchange (CBEx)
The chemotherapy shortage in the US is a pressing issue that demands a reevaluation of health policies. Dive deeper into the potential strategies for mitigating its impact, from creating a market for high-quality generics to convening a multi-stakeholder task force.
Oncology, Medical August 7th 2023